

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701TELEPHONE: 512/418-3000
FACSIMILE: 512/474-7577WRITER'S INTERNET ADDRESS:
RNAKASHIMA@FULBRIGHT.COMWRITER'S DIRECT DIAL NUMBER:
512/418-3032HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

August 22, 2000

FILE: UTSD:1219US

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on the date below:

8/22/00
Date

Richard A. Nakashima
Assistant Commissioner for Patents
Washington, DC 20231

RE: SN 09/269,598 "STEROID RECEPTOR BINDING COMPOSITIONS AND STEROID-SPARING PREPARATIONS THEREOF IN IMMUNO-SUPPRESSION AND INFLAMMATION" – Peter E. Lipsky et al. (UTSM B8994)

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449 and references (A1-A4, C1-C37).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Assistant Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/10017221/RAN.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Richard A. Nakashima
Reg. No. 42,023

RAN/mac

Encl.: As noted

RECEIVED

AUG 28 2000

GROUP 1700

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on the date below:

8/24/00
Date
Richard A. Nakashima

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Peter E. Lipsky et al.

Serial No.: 09/269,598

Filed: March 26, 1999

For: STEROID RECEPTOR BINDING
COMPOSITIONS AND STEROID-
SPARING PREPARATIONS THEREOF
IN IMMUNO-SUPPRESSION AND
INFLAMMATION

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: UTSD:1219US/RAN

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Assistant Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/10017221/RAN.

Applicants respectfully request that the listed documents be made of record in the present case.



Fulbright & Jaworski L.L.P.
600 Congress Ave., Suite 2400
Austin, Texas 78701
(512) 418-3000

Respectfully submitted,

Richard A. Nakashima
Reg. No. 42,032
Attorney for Applicants

Date:

8/22/00

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
UTSD:1219US/RANSerial No.
09/289,598Applicant
Peter E. Lipsky *et al.*Filing Date:
March 26, 1999Group:
UnknownU.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	4,005,108	1/25/77	Kupchan <i>et al.</i>	260	343.3	4/3/73
	A2	4,241,536	12/30/80	Saint-Fermin	47	58	7/7/78
	A3	4,328,309	5/4/82	Chalmers <i>et al.</i>	435	126	7/2/80
	A4	5,294,443	3/15/94	Lipsky <i>et al.</i>	424	195.1	4/3/92

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1						

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Davis <i>et al.</i> , "Regulation of human T-lymphocyte mitogenesis by antibodies to CD3," <i>J. Immun.</i> , 137:3758-3767, 1986.
	C2	Deyong, "Clinical observation of 144 cases of rheumatoid arthritis treated with glycoside of <i>Radix Tripterygium Wilfordii</i> ," <i>J. Traditional Chin. Med.</i> , 3(2):125-129, 1983.
	C3	Durand <i>et al.</i> , "Characterization of antigen receptor response elements within the interleukin-2 enhancer," <i>Mol. and Cellular Bio.</i> , 8(2):1715-1724, 1988.
	C4	Geppert and Lipsky, "Accessory cell independent proliferation of human T4 cells stimulated by immobilized monoclonal antibodies to CD3," <i>J. Immun.</i> , 138(6):1660-1666, 1987.
	C5	Gillis <i>et al.</i> , "T cell growth factor: parameters of production and a quantitative microassay for activity," <i>J. Immun.</i> , 120(6):2027-2032, 1978.
	C6	Gorman <i>et al.</i> , "Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells," <i>Mol. and Cellular Bio.</i> , 2(9):1044-1051, 1982.
	C7	Herzog <i>et al.</i> , "Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells," <i>J. Autoimmunity</i> , 2:627-642, 1989.


EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)	Attorney Docket No. UTSD:1219US/RAN	Serial No. 09/269,598
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant Peter E. Lipsky <i>et al.</i>	
(Use several sheets if necessary)	Filing Date: March 26, 1999	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>



RECEIVED
AUG 28 2000
GROUP 1700

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C8	Jelinek <i>et al.</i> , Human peripheral Blood B lymphocyte subpopulations: functional and phenotypic analysis of surface IgD positive and negative subsets," <i>J. Immun.</i> , 136(1):83-92, 1986.
	C9	Jiang, "Exploration of the treatment of nephritic syndrome with polyglycosides of <i>Tripterygium wilfordii</i> hook," <i>Chinese J. Ped.</i> , 20(4):201-202, 1982.
	C10	Kirkham <i>et al.</i> , "Response to monoclonal CD7 antibody in rheumatoid arthritis," <i>The Lancet</i> , 1:589, 1989
	C11	Kyle <i>et al.</i> , "Beneficial effect of monoclonal antibody to interleukin 2 receptor on activated T cells in rheumatoid arthritis," <i>Ann. Rheumatic Dis.</i> , 48:428-429, 1989.
	C12	Kupchan, "Novel plant-derived tumor inhibitors and their mechanisms of action," <i>Cancer Treat. Rep.</i> , 60(8):1115-1126, 1976.
	C13	Makar, "Non-sterol regulation of low density lipoprotein receptor gene expression in T cells," <i>J. Lipid Res.</i> , 35:1888-1895, 1994.
	C14	Owaki <i>et al.</i> , Raf-1 is required for T cell IL2 production," <i>EMBO J.</i> , 12(11):4367-4373, 1993.
	C15	Rosenberg and Lipsky, "Monocyte dependence of pokeweed mitogen induced differentiation of immunoglobulin-secreting cells from human peripheral blood mononuclear cells," <i>J. Immun.</i> , 122(3):926-931, 1979.
	C16	Rosenstreich <i>et al.</i> , "The Peritoneal exudate lymphocyte: I. Differences in antigen responsiveness between peritoneal exudate and lymph node lymphocytes from immunized guinea pigs," <i>J. Experimental Med.</i> , 134:1170-1185, 1971.
	C17	Splawski and Lipsky, "Antigen-induced proliferation and immunoglobulin A secretion by a human-human hybridoma," <i>J. Immun.</i> , 139:1432-1437, 1987.
	C18	Thiele <i>et al.</i> , "Phenotype of the accessory cell necessary for mitogen-stimulated T and B cell responses in human peripheral blood: delineation by its sensitivity to the lysosomotropic agent, L-leucine methyl ester," <i>J. Immun.</i> , 131(5):2282-2290, 1983.
	C19	Moreno and Lipsky, "Differential ability of fixed antigen-presenting cells to stimulate nominal antigen-reactive and alloreactive T4 lymphocytes," <i>J. Immun.</i> , 136(10):3579-3587, 1986.


EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)


 Atty. Docket No.
 UTSD:1219US/RAN

 Serial No.
 09/269,598
RECEIVED

List of Patents and Publications for Applicant's

 Applicant
 Peter E. Lipsky *et al.*

AUG 28 2000

INFORMATION DISCLOSURE STATEMENT

GROUP 1700

(Use several sheets if necessary)

 Filing Date:
 March 26, 1999

 Group:
 Unknown

 U.S. Patent Documents
See Page 1

 Foreign Patent Documents
See Page 1

 Other Art
See Page 1
Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C20	Weiss <i>et al.</i> , "The role of the T3/antigen receptor complex in T-cell activation," <i>Ann. Rev. Immunol.</i> , 4:593-619, 1986.
	C21	Tao <i>et al.</i> , "Mechanism of treatment of rheumatoid arthritis with <i>Tripterygium wilfordii</i> hook F: I. Effect of T2 on secretion of total IgM and IgM-RF by PBMC," <i>Acta. Acad. Med. Sinicae</i> , 10:361-364, 1988.
	C22	Tao <i>et al.</i> , "A prospective, controlled, double blind, cross-over study of <i>Tripterygium wilfordii</i> hook F in the treatment of rheumatoid arthritis," <i>Chinese Med. J.</i> , 102(5):327-332, 1989.
	C23	Zalkow <i>et al.</i> , "Semisynthetic pyrrolizidine alkaloid N-oxide antitumor agents. Esters of heliotridine," <i>J. Med. Chem.</i> , 31:1520-1526, 1988.
	C24	Zheng <i>et al.</i> , "Effects of total glycosides of <i>Tripterygium wilfordii</i> on reproductive organs of experimental animal: II. Experiments in female rats," <i>Acta Acad. Med. Sinicae</i> , 7(4):256-259, 1985.
	C25	Zheng <i>et al.</i> , "Studies on toxicity of total glycosides in <i>Tripterygium wilfordii</i> ," <i>Acta Acad. Med. Sinicae</i> , 5(3):73-78, 1983.
	C26	Zheng <i>et al.</i> , "Effects of total glycosides of <i>Tripterygium wilfordii</i> on animal reproductive organs: I. Experiments of male rats," <i>Acta Acad. Med. Sinicae</i> , 7(1):1-5, 1985.
	C27	Zheng <i>et al.</i> , "Antineoplastic action of triptolide and its effect on the immunologic functions in mice," <i>Acta Pharmacologica Sinicae</i> , 2(2):128-131, 1981.
	C28	Zheng <i>et al.</i> , "Studies on pharmacological actions of total glycosides in <i>Tripterygium wilfordii</i> ," <i>Acta Acad. Med. Sinicae</i> , 5(1):1-8, 1983.
	C29	Zhang <i>et al.</i> , "Studies on diterpenoids from <i>Tripterygium wilfordii</i> ," <i>Acta Acad. Med. Shanghai</i> , 13(4):267-272, 1986.
	C30	Zhang <i>et al.</i> , "Inhibitory effect of tripterine on proliferation of lymphocytes in mice," <i>Acta Pharmacologica Sinicae</i> , 7(1):85-88, 1986.
	C31	Kuang <i>et al.</i> , "Effect of thioridazine and chlorpromazine on ECG and serum potassium level - ECG of glucose load of 40 cases," ABSTRACT, <i>Chung Hua Shen Ching Ching Shen Ko Tsa Chih</i> , 21(5):297-299, 1988.

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

List of Patents and Publications for Applicant

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



Atty. Docket No.

UTSD:1219US/RAN

Serial No.

09/269,598

Applicant

Peter E. Lipsky *et al.*

Filing Date:

March 26, 1999

Group:

Unknown

RECEIVED

AUG 28 2000

GROUP 1700

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C32	Kuang <i>et al.</i> , "Effect of TCM on primary hypothyroidism in relationship to nuclear T ₃ receptors in lymphocytes," ABSTRACT, <i>Chin. J. Integr. Med.</i> , 8(11), 1998.
	C33	Pan <i>et al.</i> , "Effect of tripterygium wilfordii on nephritis of anaphylactoid purpura," <i>Proc. CAMS and PUMC</i> , 2(1):45-47, 1987.
	C34	Pan <i>et al.</i> , "Tripterygium wilfordii in the treatment of nephritis of anaphylactoid purpura," ABSTRACT, <i>Acta Acad. Med. Sinicae</i> , 9(6):463-465, 1987.
	C35	Chen <i>et al.</i> , "The lactones from threewingnut (<i>Tripterygium wilfordii</i> hook F) in Hubei," ABSTRACT (130686), <i>Zhongcaoyao</i> , 17(6), 242-245, 1986.
	C36	Zalkow <i>et al.</i> , "Macrocyclic pyrrolizidine alkaloids from <i>Senecio anonymus</i> . Separation of a complex alkaloid extract using droplet counter-current chromatography," <i>J. Natural Products</i> , 51(4):690-702, 1988.
	C37	Kupchan <i>et al.</i> , "Triptolide and triptidiolide, novel antileukemic diterpenoid triepoxides from <i>Tripterygium wilfordii</i> ", <i>J. Am. Chem. Soc.</i> , 94(20):7194-7195, 1972.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)